2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2022, 40: 3383-3393. PMID: 35452273, DOI: 10.1200/jco.22.00227.Peer-Reviewed Original ResearchConceptsProgression-free survivalCell lung cancerUnresectable stage IIIConcurrent chemoradiotherapyLung cancerEastern Cooperative Oncology Group performance status 0/1Stage IIITreatment-emergent adverse eventsPerformance status 0/1Objective response ratePrimary end pointPhase II studyPhase III trialsStandard of careSignificant safety signalsPFS ratesConsolidation therapyOpen labelII studyIII trialsOverall survivalAdverse eventsDurvalumabSafety signalsMonalizumab
2021
LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
Martinez-Marti A, Majem M, Barlesi F, Costa E, Chu Q, Monnet I, Sanchez A, Dahkil S, Camidge D, He P, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst R. LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Annals Of Oncology 2021, 32: s1320. DOI: 10.1016/j.annonc.2021.08.2121.Peer-Reviewed Original Research
2020
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).
Redman M, Papadimitrakopoulou V, Minichiello K, Gandara D, Hirsch F, Mack P, Schwartz L, Vokes E, Ramalingam S, Leighl N, Bradley J, LeBlanc M, Malik S, Miller V, Sigal E, Adam S, Blanke C, Kelly K, Herbst R. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). Journal Of Clinical Oncology 2020, 38: 9576-9576. DOI: 10.1200/jco.2020.38.15_suppl.9576.Peer-Reviewed Original ResearchBiomarker-driven studiesLung-MAPNational Clinical Trials NetworkClinical Trials NetworkSquamous lung cancerNational Cancer InstituteLung cancerTherapy questionsCancer InstituteUnmet needSuccess of PDMaster protocolsTrials NetworkPatientsBiomarker resultsSqNSCLCRegulatory approvalTherapyDurvalumabIpilimumabNivolumabTrial partsFoundationOneNSCLCS1400
2019
P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Herbst R, Barlesi F, Paz-Ares L, Raben D, Aggarwal C, Bothos J, Samadani R, He P, Angra N, Martinez P. P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s450-s451. DOI: 10.1016/j.jtho.2019.08.931.Peer-Reviewed Original Research
2017
83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A
Papadimitrakopoulou V, Redman M, Borghaei H, Waqar S, Robert F, Kiefer G, McDonough S, Herbst R, Kelly K, Gandara D. 83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A. Annals Of Oncology 2017, 28: ii29. DOI: 10.1093/annonc/mdx091.003.Peer-Reviewed Original Research